All lobbying filings

THE NICKLES GROUP, LLC

THE NICKLES GROUP, LLC filed a Q4 report for EMERGENT BIOSOLUTIONS on January 20, 2026, reporting $40,000 in lobbying income.

Lobbying for EMERGENT BIOSOLUTIONS · Pharmaceutical company.

All filings by THE NICKLES GROUP, LLC · Everything EMERGENT BIOSOLUTIONS has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$40,000

What the client paid this registrant for the period.

Client based in

Maryland

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Budget/Appropriations

Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY2026. Opioid and heroin addiction legislation, naloxone access and awareness.

Health Issues

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act, Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY2026, Opioid crisis legislation, naloxone access and awareness, FY2026 NDAA provisions related to biological and chemical defense and access to naloxone.

Defense

National Defense Authorization Act for FY2026, provisions related to biological and chemical defense and access to naloxone.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.